Efalizumab: A Biological Agent for the Treatment of Psoriasis

E-ISSN： 1876-1038|1|2|165-168

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.1, Iss.2, 2006-05, pp. : 165-168

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efalizumab in the treatment of psoriasis

By Della Croce Christine Kwan Wong Vicky Lebwohl Mark G

Therapy, Vol. 1, Iss. 2, 2004-11 ,pp. : 197-202

Future Medicine

Access to resources Recommend Favorite

Indirubin: a novel topical agent in the treatment of psoriasis

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 1, 2018-01 ,pp. : 21-21

John Wiley & Sons Inc

Access to resources Recommend Favorite

Monoclonal gammopathy of undetermined significance (MGUS) in patients with psoriasis may be associated with long‐term treatment with efalizumab, but not with anti‐TNF‐α treatments or ustekinumab

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 3, 2015-03 ,pp. : 609-611

John Wiley & Sons Inc

Access to resources Recommend Favorite

A patient‐centred approach to biological treatment decision making for psoriasis: an expert consensus

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 12, 2015-12 ,pp. : 2390-2398

John Wiley & Sons Inc

Access to resources Recommend Favorite

The ‘switcher’ patient profile in psoriasis treatment: from traditional to biological and from biological to traditional systemic drugs

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 1, 2015-07 ,pp. : 256-258

John Wiley & Sons Inc

Access to resources Recommend Favorite